SZN 113
Alternative Names: SZN-113Latest Information Update: 03 Dec 2024
Price :
$50 *
At a glance
- Originator Surrozen
- Class Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Wnt signalling pathway stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dry macular degeneration; Fuchs' endothelial dystrophy
Most Recent Events
- 06 Nov 2024 Preclinical trials in Dry macular degeneration in USA (Parenteral) prior to November 2024 (Surrozen pipeline, November 2024)
- 06 Nov 2024 Preclinical trials in Fuchs' endothelial dystrophy in USA (Parenteral) prior to November 2024 (Surrozen pipeline, November 2024)
- 06 Nov 2024 Pharmacodynamics data from preclinical studies in Dry macular degeneration and Fuchs' endothelial dystrophy released by Surrozen